Cross-Cultural Connections
The daughter of a historian for the United States government and an instructor of comparative literature, Blau was born in England and experienced a culturally rich childhood. "My parents were Austrian and immigrated to the [United States] during World War II. We grew up listening to opera and living and travelling throughout Europe," she recalls. She holds dual United States and British citizenship.
Blau notes that in high school in Germany, she studied languages and literature. But as an undergraduate at the University of York in England, she chose to study biology and wrote a thesis on liver regeneration, foreshadowing her later interests. Her college advisor, biochemist J. Ramsey Bronk, the son of former National Academy of Sciences President Detlev Bronk, suggested she return to the United States to pursue graduate school, and in the fall of 1969, she enrolled at Harvard University. There, she met biologist Fotis Kafatos, with whom she studied silk moth eggshell morphogenesis.
While at Harvard, Blau cultivated an interest in genetics by taking courses at the medical school and participating in a genetic counseling clinic. "Back then, we were limited in terms of what we could technically do. You could map genes to chromosomes, but that was about it."
Dissecting Duchenne
After completing her doctorate, Blau left for the west coast. She joined geneticist Charles Epstein at the University of California, San Francisco as a postdoctoral fellow in the Department of Biochemistry and Biophysics and as a genetic counselor before accepting a position in 1978 at Stanford University, where she was one of two women hired on tenure track in the basic sciences in the medical school. Blau has remained at the northern California institution ever since.
For Blau, the experience as a genetic counselor primed her for the work she would later pursue and exposed her to the human aspect of biological research. "It was fascinating because we dealt with disease in the context of the individual, the family, and the community: from the genetic cause to the disrupted signal transduction pathways to predictions of recurrence and prognosis," she says.
During this time, Blau met with the families of patients with Duchenne muscular dystrophy (DMD). The recessive, X-linked, muscle-wasting disease affects nearly 1 in 3,500 boys, and remains a major cause of childhood mortality for which there is currently no cure.
Blau's work on DMD began in the early 1980s when she identified defective myoblasts, precursor muscle cells, as a culprit (2) . Since then, her research on the disease has unveiled its causes and mechanism of progression. For example, mice with mutations in dystrophin, the muscle protein implicated in skeletal muscle degeneration and heart failure in DMD (3), show relatively mild symptoms of the disease. Blau's group hypothesized that the longer telomeres of mouse muscle stem cells, compared with shorter human telomeres, might play a protective role. The researchers showed that in mice with defective telomerase, an enzyme that maintains telomere length, the dystrophin mutation led to full manifestation of muscular dystrophy, effectively creating a mouse model of the disease. Treatment with normal muscle stem cells reversed the progression of the dystrophy in the animals' skeletal muscles and provided a clue that human DMD results from muscle stem cell exhaustion (4) .
Moreover, the mice with humanized telomeres suffered from dilated cardiomyopathy, similar to DMD patients (5) . Her group's subsequent demonstration that the cardiomyocytes of DMD patients have 50% telomere lengths relative to both other heart cells and unaffected individuals revealed telomere shortening as a hallmark of the disease (5, 6). Blau's group has also discovered a way to rapidly and safely extend telomeres, suggesting the promise of the approach for heart and muscle rejuvenation (7).
Dynamic Differentiation
Blau made her first major discovery while trying to identify transacting activators, which are transcription factors that promote gene expression, at a time when only transacting repressors were known. She started by creating heterokaryons, which are cells with more than one nucleus, by fusing differentiated, multinucleated mouse muscle cells with human amniotic cells. "This is significant," she notes, "because we were thinking of prenatal detection as well as treating muscle disorders."
In a series of landmark studies in the early 1980s, Blau and her colleagues demonstrated that differentiation, which was thought of as a terminal cellular state, was in fact reversible, and that under the right conditions previously inactive genes could be activated by cytoplasmic proteins. Identification of these transacting activators was a paradigm shift in biology (8) (9) (10) (11) . Their effect proved that the differentiated state is not terminal but subject to change.
"There was tremendous excitement at the result," Blau recollects. Her reprogrammed heterokaryon cells graced the cover of the "Frontiers in Biology" issue of Science in 1985 and were highlighted in an article entitled "Plasticity of the differentiated state" (10) . Work from her laboratory revealed that a cell's differentiated state requires continuous regulation and that the balance or ratio of activators and repressors inside a cell was crucial to maintaining the terminal state (12) . Further research from her laboratory found similarities between differentiation and the process of angiogenesis, or blood vessel growth, which also relies on a balance of regulatory factors and cell types. This work challenged the prevailing notion that a protein, called vascular endothelial growth factor, could by itself repair vascular disease if delivered effectively, and invoked a crucial ratio with platelet-derived growth factor (13, 14) in the process.
Stem Cell Stimulation
Blau's wide-ranging interests and global perspective have broadened her career, from developmental biology to regenerative medicine and to advancing stem cell technologies toward clinical translation.
Muscle stem cells, for example, have proven challenging to culture in vitro, where they lose their "stemness" and potency, hindering research into regeneration. Blau's laboratory postulated that the cells, having never encountered the stiffness of a plastic culture dish, might prefer substrates that mimic the niche in which they normally reside. Her laboratory bioengineered hydrogels with differing elasticities and tracked cellular proliferation and differentiation with an automated, single cell tracking algorithm (15) .
"Muscle stem cells really care about the rigidity of the substrate on which they're grown, which impacts the cytoskeleton and a host of downstream signaling. This phenomenon turns out to be generally true for different cell types," Blau notes. When grown on an appropriate hydrogel, muscle stem cells propagate and can be injected into and repair damaged tissue (16) . This research may lead to effective stem cell-based therapeutics for heritable or acquired muscle-wasting disorders.
Age also plays a role in muscle stem cell dysfunction. Typically, tissue damage activates quiescent stem cells, but with age, the ability to repair muscle tissue decreases. Blau's laboratory uncovered the signal transduction pathways-the P38 MAP-kinase and the Jak2-Stat3 pathways-that hinder muscle stem cell activation in aging tissues (17, 18) .
In her Inaugural Article (1), Blau's group screened for compounds that could enhance muscle stem cell function during aging. They discovered that prostaglandin E2 (PGE2), an inflammatory lipid metabolite often prescribed to induce labor, rejuvenates the function of muscle stem cells. The researchers extended the discovery by treating muscle stem cells with PGE2 in vivo and found robust muscle regeneration.
"We're capitalizing on something that occurs naturally in the body and augmenting it," she notes. "The treatment with PGE2 leads to an increase in muscle stem cell function like we've never seen before." In addition, Blau's work revealed that treatment with nonsteroidal antiinflammatory drugs, such as ibuprofen, can inhibit muscle stem cell rejuvenation, a fact that should worry athletes who take the medicine to treat or prevent muscle pain after exercise. "No pain, no gain" Blau chuckles. "The clinical implications of this work could profoundly impact people's health," she adds.
Finding the Fountain of Youth
Activating the body's dormant stem cells, however, is only one part of Blau's regeneration story. "We need to understand the secrets of the newt," Blau notes. In part, the "secret of the newt" is the ability of the animal's cells to reverse the cell cycle: to dedifferentiate. If human cells in damaged tissues could dedifferentiate and multiply, as they do in animals with the ability to regenerate limbs, then humans would have a similar capability for regeneration. However, as Blau explains, "we believe that during evolution, mammals, which are longer-lived than smaller animals, lost regenerative potential as a trade-off for cancer protection during aging." She adds that her laboratory and others are looking for ways to transiently activate the dedifferentiation process and temporarily inhibit tumor-suppressor proteins in damaged tissue and postmitotic cells (19, 20) .
"If we solve dedifferentiation, we could prevent heart failure. And, coupled with our strategy for rejuvenation, we could restore function to muscles of those who are immobilized," Blau says. She adds that "if we achieve even a fraction of that, I'll be extremely happy. I've had a lot of fun in my career already. The work keeps me rejuvenated!" At the time of Blau's differentiation discovery in the early 1980s, the researchers in her laboratory were all women. "In those days, it was rare to be a woman in the sciences," she says. "'The Amazons' is what they called us," she adds, laughing, "or 'Helen's Angels.'" Blau reveals that when she became pregnant, "everyone thought 'okay, there's no way she's coming back.' But I decided that I wasn't going to be happy if I didn't return." Her two grown children, an architect and a lawyer, now practice in northern California. Her husband, David Spiegel, holds the Wilson Professorship and is Associate Chair of Psychiatry at Stanford.
Blau takes pride in her mentorship of young scientists, noting that she enjoys "attracting people from all over the world of different ages, helping them recognize their strengths and weaknesses and reach their full potential. It's a tremendous source of gratification."
